The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9, J. Virol, vol.80, pp.9831-9836, 2006. ,
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating "clinical proof-ofconcept" for AAV-neurturin (CERE-120) in Parkinson's disease, Neurobiol. Ag, vol.34, pp.35-61, 2013. ,
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice, J. Clin. Invest, vol.121, pp.2427-2435, 2011. ,
Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol. Ther, vol.19, 1971. ,
Early heart failure in the SMN 7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery, Hum. Mol. Genet, vol.19, pp.3895-3905, 2010. ,
Prevalence of serum IgG and neutralizing factors against adenoassociated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors, Hum. Gene Ther, vol.21, pp.704-712, 2010. ,
, , 2011.
, Adeno-associated virus antibody profiles in newborns, children, and adolescents, Clin. Vaccine Immunol, vol.18, pp.1586-1588
Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy, Nat. Med, vol.15, pp.1215-1218, 2009. ,
Astrogliosis as a therapeutic target for neurodegenerative diseases, Neurosci. Lett, vol.565, pp.59-64, 2014. ,
In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous, Sci. Transl. Med, vol.5, pp.189-76, 2013. ,
Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9, Gene Ther, vol.19, pp.176-181, 2011. ,
Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system, Proc. Natl. Acad. Sci. U.S.A, vol.97, pp.3428-3432, 2000. ,
The advent of AAV9 expands applications for brain and spinal cord gene delivery, Expert Opin. Biol. Ther, vol.12, pp.757-766, 2012. ,
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of ?-synuclein in midbrain dopamine neurons, Neurobiol. Dis, vol.45, pp.939-953, 2012. ,
Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques, Sci. Rep, vol.2, p.253, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01053467
Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, Mol. Ther, vol.17, pp.1187-1196, 2009. ,
, Frontiers in Molecular Neuroscience www.frontiersin.org
Levodopa gains psychostimulant-like properties after nigral dopaminergic loss, Ann. Neurol, vol.74, pp.140-144, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01153692
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs, Gene Ther, vol.19, pp.852-859, 2012. ,
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adenoassociated virus vectors, J. Virol, vol.70, pp.3227-3234, 1996. ,
New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors, Nat. Med, vol.3, pp.1295-1297, 1997. ,
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat. Biotechnol, vol.27, pp.59-65, 2008. ,
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nat. Biotechnol, vol.28, pp.271-274, 2010. ,
Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery, Mol. Ther, vol.19, pp.1025-1033, 2011. ,
Clades of adeno-associated viruses are widely disseminated in human tissues, J. Virol, vol.78, pp.6381-6388, 2004. ,
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB), Mol. Ther, vol.18, pp.570-578, 2010. ,
optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors, Hum. Gene Ther, vol.22, pp.1143-1153, 2011. ,
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates, Mol. Ther, vol.19, pp.1058-1069, 2011. ,
Vector design and considerations for CNS applications, Gene Vector Design and Application to Treat Nervous System Disorders, pp.1-9, 2011. ,
Novel tools for production and purification of recombinant adenoassociated virus vectors, Hum. Gene Ther, vol.9, pp.2745-2760, 1998. ,
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses, J. Virol, vol.82, pp.5887-5911, 2008. ,
Improved highcapacity adenoviral vectors for high-level neuron-restricted gene transfer to the CNS, J. Virol. Methods, vol.136, pp.30-37, 2006. ,
Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells, Proc. Natl. Acad. Sci. U.S.A, vol.81, pp.6466-6470, 1984. ,
Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice, BioMed Res. Intl, vol.2013, pp.1-8, 2013. ,
Structure of the mouse tyrosine hydroxylase gene, Biochem. Biophys. Res. Commun, vol.182, pp.348-354, 1992. ,
Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice, Sci. Rep, vol.3, p.1472, 2013. ,
Safety and tolerability of gene therapy with an adenoassociated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, vol.369, pp.60982-60991, 2007. ,
Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model, Science, vol.301, pp.839-842, 2003. ,
Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states, Eur. J. Neurosci, vol.27, pp.1615-1625, 2008. ,
Comparison of AAV serotypes for gene delivery to dopaminergic neurons in the Substantia Nigra, pp.1-21, 2011. ,
Crossing the rubicon, Nat. Biotechnol, vol.27, pp.42-44, 2009. ,
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors, Nat. Biotechnol, vol.24, pp.198-204, 2006. ,
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, Lancet Neurol, vol.9, issue.10, pp.70254-70258, 2010. ,
Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems, Gene Ther, vol.20, pp.69-83, 2012. ,
, , 2009.
, Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice, Gene Ther, vol.16, pp.1340-1352
Adeno-associated virus terminal repeat (TR) mutant generates selfcomplementary vectors to overcome the rate-limiting step to transduction in vivo, Gene Ther, vol.10, pp.2112-2118, 2003. ,
Adenoassociated virus general transduction vectors: analysis of proviral structures, J. Virol, vol.62, pp.1963-1973, 1988. ,
Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis, Ann. Neurol, vol.57, pp.773-776, 2005. ,
Overcoming preexisting humoral immunity to AAV using capsid decoys, Sci. Transl. Med, vol.5, pp.194-92, 2013. ,
Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors, Brain Res, vol.1389, pp.19-26, 2011. ,
Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors, Nat. Biotechnol, vol.21, pp.1040-1046, 2003. ,
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons, Nat. Neurosci, vol.10, pp.615-622, 2007. ,
Adeno-associated virus vectors and neurological gene therapy, Neuroscientist, 2014. ,
Drug and gene targeting to the brain with molecular Trojan horses, Nat. Rev. Drug Discov, vol.1, pp.131-139, 2002. ,
High-efficiency Transduction of the Mouse Retina by tyrosine-mutant AAV serotype vectors, Mol. Ther, vol.17, pp.463-471, 2008. ,
Viral vectors in primate research: examples from Parkinson's disease research, Viral Vector Approaches in Neurobiology and Brain Diseases, pp.331-341, 2014. ,
, Frontiers in Molecular Neuroscience www.frontiersin.org
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer, Mol. Ther, vol.19, pp.1070-1078, 2011. ,
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity, J. Virol, vol.76, pp.791-801, 2002. ,
Insertional mutagenesis of AAV2 capsid and the production of recombinant virus, Virology, vol.265, pp.274-285, 1999. ,
Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system, FASEB J, vol.25, pp.3505-3518, 2011. ,
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates, Hum. Gene Ther, vol.23, pp.382-389, 2012. ,
Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells, Proc. Natl. Acad. Sci. U.S.A, vol.79, pp.2077-2081, 1982. ,
The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9, Nat. Biotechnol, vol.27, pp.804-805, 2009. ,
Terminal N-linked galactose is the primary receptor for adeno-associated virus 9, J. Biol. Chem, vol.286, pp.13532-13540, 2011. ,
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, N. Engl. J. Med, vol.361, pp.1651-1661, 2009. ,
Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder, Mol. Ther, vol.19, pp.860-869, 2011. ,
Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum, Gene Ther, vol.21, pp.143-148, 2010. ,
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain, Hum. Gene Ther, vol.18, pp.195-206, 2007. ,
Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery, Mol. Pain, vol.5, p.52, 2009. ,
Tailoring the AAV vector capsid for gene therapy, Gene Ther, vol.16, pp.311-319, 2008. ,
Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed, Mol. Ther, vol.18, pp.2064-2074, 2010. ,
Adeno-associated virus (AAV) gene therapy for neurological disease, Neuropharmacology, vol.69, pp.82-88, 2013. ,
Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration, Mol. Genet. Metab, vol.106, pp.131-134, 2012. ,
Adeno-associated virus serotypes: vector toolkit for human gene therapy, Mol. Ther, vol.14, pp.316-327, 2006. ,
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus, J. Virol, vol.72, pp.2224-2232, 1998. ,
MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNSrestricted transgene expression, Mol. Ther, vol.19, pp.526-535, 2011. ,
A combination of mutations enhances the neurotropism of AAV-2, Virology, vol.341, pp.203-214, 2005. ,
Adenovirusadeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum, Gene Ther, vol.20, pp.922-929, 2009. ,
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system, Mol. Ther, vol.19, pp.1440-1448, 2011. ,
A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease, Neurobiol. Dis, vol.14, pp.365-379, 2003. ,
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses, Proc. Natl. Acad. Sci. U.S.A, vol.105, pp.7827-7832, 2008. ,
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol. Ther, vol.16, pp.1073-1080, 2008. ,